It’s well known that preeclampsia, a condition characterized by a progressive rise in a pregnant woman’s blood pressure and appearance of protein in the urine, can have negative, even life-threatening impacts on the health of both mother and baby. Now, NIH-funded researchers have documented that preeclampsia is also taking a very high toll on our nation’s economic well-being. In fact, their calculations show that, in 2012 alone, preeclampsia-related care cost the U.S. health care system more than $2 billion.
These findings are especially noteworthy because preeclampsia rates in the United States have been steadily rising over the past 30 years, fueled in part by increases in average maternal age and weight. This highlights the urgent need for more research to develop new and more effective strategies to protect the health of all mothers and their babies.
Tags: baby, birth, birth complications, birth outcomes, disease incidence, early delivery, gestation, gynecology, health care, health economics, health-care costs, high blood pressure, infants, maternity, motherhood, OB-GYN, obstetrics, placenta, preeclampsia, pregnancy, pregnancy complications, prenatal care, preterm births, thrombocytopenia, treatment, women's health